This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Treszezamsky, A. D. Articles by Powell, S. N. Search for Related Content PubMed PubMed Citation Articles by Treszezamsky, A. D. Articles by Powell, S. N.

BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II

¹ Department of Radiation Oncology, Massachusetts General Hospital; ² Department of Radiation Oncology, Boston University Medical Center, Boston, Massachusetts; and ³ Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri

Requests for reprints: Simon N. Powell, Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park, St. Louis, MO 63108. Phone: 314-362-9700; Fax: 314-747-5498; E-mail: snpowell{at}radonc.wustl.edu.

The function of BRCA1 and BRCA2 in DNA repair could affect the sensitivity of cells to cytotoxic agents, and would therefore be an important component of planning therapy for breast and ovarian cancers. Previously, both BRCA1- and BRCA2-deficient tumors were shown to be sensitive to mitomycin C, and the mechanism was presumed to be a defect in the repair of interstrand crosslinks by homologous recombination. Here, we show that both BRCA1 and BRCA2 determine the sensitivity to the cytotoxic drug, etoposide, using genetic complementation of BRCA-deficient cells. Etoposide is known to bind to topoisomerase II and prevent the resolution of the "cleavable complex," in which one DNA duplex is passed through a second duplex. The specificity of this BRCA-dependent sensitivity was confirmed by the use of aclarubicin, which is a catalytic inhibitor of topoisomerase II and prevents the formation of the cleavable complex. In the presence of aclarubicin, the differential sensitivity of BRCA-proficient and BRCA-deficient cells was lost. Thus, etoposide requires the presence of topoisomerase II to show specific sensitization in the absence of the function of BRCA1 or BRCA2. We conclude that homologous recombination is used in the repair of DNA damage caused by topoisomerase II poisons. Overall, these results suggest that etoposide is a potentially useful drug in the treatment of BRCA-deficient human cancers. [Cancer Res 2007;67(15):7078–81]

This article has been cited by other articles:

				C. Oakman, E. Moretti, C. Sotiriou, G. Viale, and A. Di Leo Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy J Natl Cancer Inst, November 5, 2009; (2009) djp402v1. [Full Text] [PDF]

				K. I. Pritchard, F. O'malley, L. Shepherd, M. N. Levine, D. Tu, V. Bramwell, I. Andrulis, and S. Chia Response J Natl Cancer Inst, November 5, 2009; (2009) djp403v1. [Full Text] [PDF]

				P. Okunieff, L. A. Kachnic, L. S. Constine, C. D. Fuller, L. E. Gaspar, D. F. Hayes, J. Hooks, C. Ling, F. L. Meyskens Jr., P. A. Philip, et al. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 Clin. Cancer Res., September 15, 2009; 15(18): 5663 - 5670. [Abstract] [Full Text] [PDF]

				H. Willers, A. G. Taghian, C.-M. Luo, A. Treszezamsky, D. C. Sgroi, and S. N. Powell Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies Mol. Cancer Res., August 1, 2009; 7(8): 1304 - 1309. [Abstract] [Full Text] [PDF]

				M. Santarosa, L. Del Col, E. Tonin, A. Caragnano, A. Viel, and R. Maestro Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers Mol. Cancer Ther., April 1, 2009; 8(4): 844 - 854. [Abstract] [Full Text] [PDF]

				T. Hucl, C. Rago, E. Gallmeier, J. R. Brody, M. Gorospe, and S. E. Kern A Syngeneic Variance Library for Functional Annotation of Human Variation: Application to BRCA2 Cancer Res., July 1, 2008; 68(13): 5023 - 5030. [Abstract] [Full Text] [PDF]